These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 23443308)

  • 61. Is it rational to continue anti-neoplastics with minimal toxicity even after progression in patients with no other options? Possibly yes.
    Sezer A; Sumbul AT; Abali H
    Asian Pac J Cancer Prev; 2014; 15(2):1061-2. PubMed ID: 24568451
    [No Abstract]   [Full Text] [Related]  

  • 62. Those Who Cannot Remember the Past are Condemned to Repeat It.
    Raymond DP
    Ann Surg Oncol; 2020 Mar; 27(3):623-624. PubMed ID: 31912258
    [No Abstract]   [Full Text] [Related]  

  • 63. Beyond the standard of care: the role of cytopathology in molecular testing of cancer.
    Kulesza P
    Cancer Treat Res; 2014; 160():273-82. PubMed ID: 24092374
    [No Abstract]   [Full Text] [Related]  

  • 64. Contribution of Cancer-Targeting Drugs toward Faster Clinical Application.
    Yoon S; Kim HS
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742888
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Late treatment effects: reframing the questions.
    Murphy BA
    Lancet Oncol; 2009 Jun; 10(6):530-1. PubMed ID: 19482238
    [No Abstract]   [Full Text] [Related]  

  • 66. [Not Available].
    Recenti Prog Med; 2019; 110(7):376-377. PubMed ID: 31379377
    [No Abstract]   [Full Text] [Related]  

  • 67. Differentiating agents in malignant disease.
    Bruetman DG; Harris JE; Anderson KM
    Med Pediatr Oncol; 1991; 19(2):71-83. PubMed ID: 2011099
    [No Abstract]   [Full Text] [Related]  

  • 68. Preface.
    Rueff J; Rodrigues AS
    Methods Mol Biol; 2016; 1395():v-vii. PubMed ID: 27340700
    [No Abstract]   [Full Text] [Related]  

  • 69. Cancer chemotherapeutic agents.
    Krakoff IH
    CA Cancer J Clin; 1981; 31(3):130-40. PubMed ID: 6784889
    [No Abstract]   [Full Text] [Related]  

  • 70. Measure once or twice -- does it really matter?
    Hilsenbeck SG; Von Hoff DD
    J Natl Cancer Inst; 1999 Mar; 91(6):494-5. PubMed ID: 10088614
    [No Abstract]   [Full Text] [Related]  

  • 71. The radialist's religious fervor: Praise the Lord, I Am a Believer in Treating CTOs and the Radial Approach.
    Heuser RR
    Catheter Cardiovasc Interv; 2015 Jun; 85(7):1130-1. PubMed ID: 25999273
    [No Abstract]   [Full Text] [Related]  

  • 72. Pancreatic cancer: Dodging immunosuppression.
    Seton-Rogers S
    Nat Rev Cancer; 2016 Jul; 16(8):480-1. PubMed ID: 27451955
    [No Abstract]   [Full Text] [Related]  

  • 73. Dodging the genes.
    Bushman F
    Curr Biol; 1993 Aug; 3(8):533-5. PubMed ID: 15335696
    [No Abstract]   [Full Text] [Related]  

  • 74. Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies.
    Mauri G; Pizzutilo EG; Amatu A; Bencardino K; Palmeri L; Bonazzina EF; Tosi F; Carlo Stella G; Burrafato G; Scaglione F; Marsoni S; Siravegna G; Bardelli A; Siena S; Sartore-Bianchi A
    Cancer Treat Rev; 2019 Feb; 73():41-53. PubMed ID: 30616224
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Retreatment after secondary resistance or mixed response: a pilot study.
    Naing A; Agarwal R; Falchook G; Hong DS; Janku F; Wheler J; Fu S; Kurzrock R
    Oncology; 2013; 85(6):350-5. PubMed ID: 24335388
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Progressive Disease with Mixed Response After Immunotherapy in Non-Small Cell Lung Cancer.
    Lv J; Yan W; Zhang R; Chen X; Ren Z; Chen D; Yu J
    J Inflamm Res; 2024; 17():6317-6327. PubMed ID: 39281775
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Navigating uncharted territory: a case report and literature review on the remarkable response to personalized crizotinib containing combinational therapy in a pazopanib refractory patient with novel alterations.
    Aydın E; Tokat ÜM; Özgü E; Adibi A; Tutar O; Kurzrock R; Demiray M
    Ther Adv Med Oncol; 2024; 16():17588359241247023. PubMed ID: 38645422
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cancer: slaying the nine-headed Hydra.
    Adashek JJ; Subbiah V; Westphalen CB; Naing A; Kato S; Kurzrock R
    Ann Oncol; 2023 Jan; 34(1):61-69. PubMed ID: 35931318
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Hepatocellular carcinoma: Where there is unmet need.
    Bupathi M; Kaseb A; Meric-Bernstam F; Naing A
    Mol Oncol; 2015 Oct; 9(8):1501-9. PubMed ID: 26160430
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations.
    Wheler JJ; Tsimberidou AM; Falchook GS; Zinner RG; Hong DS; Fok JY; Fu S; Piha-Paul SA; Naing A; Kurzrock R
    Mol Cancer Ther; 2013 Oct; 12(10):2167-75. PubMed ID: 23963360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.